NeoGenomics Inc. Common Stock vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? NeoGenomics Inc. Common Stock trades at $17.17 (market cap $2.17B), while Vanguard S&P 500 Growth Index Fund ETF trades at $84.39 (market cap $27.10B). The key difference: Vanguard S&P 500 Growth Index Fund ETF is far larger — about 12.5× NeoGenomics Inc. Common Stock's market cap, and NeoGenomics Inc. Common Stock is more actively traded (1,615,943 versus 1,536,013). Which is the better fit depends on your goals — on Pluang, investors hold NeoGenomics Inc. Common Stock for 0 Days and Vanguard S&P 500 Growth Index Fund ETF for 56 Days on average.
| NEO | VOOG | |
|---|---|---|
Market Cap | $2.17B | $27.10B |
Volume | 1,615,943 | 1,536,013 |
Sector | Health | Broad Market / Factor |
52-Week High | $19.91 | $87.81 |
52-Week Low | $7.19 | $65.32 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $2.47B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VOOG trades at $86.9, down slightly by 0.02% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF, tracking S&P 500 growth stocks, has seen strong institutional buying and positive media coverage highlighting its long-term growth potential and low expense ratio of 0.07%.
The outlook remains favorable for growth-oriented investors, supported by historical outperformance and sector concentration in technology. Key risks include market volatility and reliance on mega-cap tech stocks, but analyst sentiment and institutional inflows suggest continued confidence in its strategy.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
NeoGenomics, Inc. is a US cancer diagnostics company that provides genomic and pathology testing services, offering an oncology-focused testing menu used by oncologists, pathologists, and hospital systems across the cancer care continuum.
Read more on NEO →VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →